enGene Therapeutics Inc.
About enGene Therapeutics Inc.
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$117.3M
- Total assets
- $221.5M
- Market cap
- $109.9M
Source: SEC EDGAR · updated Jun 8, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $123.2M
- Operating income
- -$123.2M
- Income tax
- $0
- Net income
- -$117.3M
- EPS (basic)
- $2.29
- EPS (diluted)
- $2.29
Balance sheet
- Total assets
- $221.5M
- Current assets
- $201.4M
- Total liabilities
- $53.8M
- Current liabilities
- $32.0M
- Shareholders’ equity
- $167.7M
Cash flow
- Operating cash flow
- -$99.2M
- Investing cash flow
- -$25.1M
- Financing cash flow
- $1.5M
- Net cash flow
- -$122.9M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $109.9M
- P/E ratio
- 0.7
- EPS (diluted)
- $2.29
- Dividend yield
- 91.87%
- Shares outstanding
- 66.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 1, 2023
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $117.3M.
- Trading 86% below its 52-week high.
- Pays a dividend yielding about 91.87% annually.
- Valued at a price-to-earnings (P/E) ratio of 0.7.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review enGene Therapeutics Inc..
Write a review
News about enGene Therapeutics Inc.
News & sentiment via Polygon.io
